Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

NCT04821778 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

2000

Enrollment

OTHER

Sponsor class

Conditions

Esophagus Cancer
Esophagogastric Junction Cancer
Chemoradiation
Targeted Therapy
Immunotherapy
Chemotherapy Effect

Interventions

RADIATION: Radiotherapy
DRUG: Platinum based chemotherapy
DRUG: Paclitaxel based chemotherapy
DRUG: Immunotherapy
DRUG: 5-FU Analog based chemotherapy
DRUG: Nimotuzumab

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences